Skip to main content
. 2020 Mar 3;45(5):1341–1350. doi: 10.3892/ijmm.2020.4521

Figure 4.

Figure 4

SB inhibits RCC metastasis through downregulating the Wnt/β-catenin pathway. (A) β-catenin-overexpressing 786-O cells were treated with 60 μM SB for 24 h. Expression of EMT associated markers were determined by western blotting. (B) Transwell migration and invasion assays were performed in β-catenin-overexpressing 786-O cells following treatment with 60 μM SB. Magnification, ×100. Scale bar, 20 μm. The experiment was repeated three times. **P<0.01. (C) ACHN cells were transfected with two different siRNA targeting β-catenin for 24 h and treated with DMSO or SB for another 24 h. Expression of EMT associated markers were determined by western blotting. (D) Transwell migration and invasion assays were performed on ACHN cells transfected with β-catenin siRNA sequence 1 following treatment with 60 μM SB treatment. Magnification ×100. Scale bar, 20 μm. The experiment was repeated three times. #P>0.05, *P<0.05 and **P<0.01. RCC, renal cell carcinoma; EMT, epithelial-mesenchymal transition; si, small interfering; SB, silibinin; N, neural; E, epithelial.